Keywords
pediatrics
epidemiology
How to Cite
Abstract
Chronic myeloid leukemia (CML) is not a common pathology in childhood, representing 2-3% of leukemia in children and adolescents with an incidence of 0.6 to 1.2 / million children / year that increases with the age.
The clinical characteristics are different in this population, compared to adults, tending to present
more aggressive characteristics (greater white blood cell count, greater spleen size in proportion to body
size, higher frequency of advanced stages in diagnosis); show a distribution of BCR-ABL1 breakpoints
that resemble adult acute lymphoblastic leukemia with positive Philadelphia chromosome, and have a higher proportion of mutated cancer driver genes.
With the appearance of tyrosine kinase inhibitors (ITK), the prognosis of this disease has changed, with a life expectancy in adult patients almost identical to that of a healthy population of the same age.
There is no protocol in Argentina aimed exclusively at pediatric patients. Nor do we have an dequate registry in our country, and each professional follows the guidelines of different adult patient guides.
The objective of this work is to initiate a national registry with data of our patients and in this way evaluate the characteristics of this population, allowing in the future the creation of guidelines for the diagnosis, management, treatment and monitoring of these patients.
References
2. Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am. 2015;62:107-119.
3. Mattano L, Nachman J, Ross J, Stock W. Leukemias. In: Bleyer A, O’Leary M, Barr R, Ries LAG, eds. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute, NIH; 2006:39-51. https://seer.cancer.gov/archive/publications/aya/aya_mono_complete.pdf [Accessed December 29, 2018]. Pub. No. 06–5767.
4. Moreno, F.; Chaplin M.A.; et all. Registro oncopediátrico hospitalario argentino- 6a ed. -
Ciudad Autónoma de Buenos Aires: Instituto Nacional del Cáncer, 2018.
5. Millot F, Traore P, Guilhhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140-143.
6. Pemmaraju N, Kanarjian H, Shan J, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97:1029-1035.
7. De la Fuente J, Baruchel A, Biondi A, et al. Recommendations for the management of CML in children and young people up to the age of 18 years. Brit J Haematol. 2014;167:33-47.
8. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119:1821-1830.
9. NCCN. NCCN clinical practice guidelines in oncology; chronic myelogenous leukemia, Version 1.2019: National Comprehensive Cancer Network. 2018.
10. Baccarani M, Deininger MW, Rosti G et al. European Leukemia Net ecommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
11. Fantl, D. "Guías de Diagnóstico y Tratamiento de la Sociedad Argentina de Hematología Edición 2019." Revista Hematología 22.Extraordin (2018).
12. Samis J, Lee P,ZimmermanP, et al.Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63:1332-1338.
13. Krumbholz M, Karl M, Tauer JT, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer. 2012;51:1045-1053.
14. Samis J, Lee P,ZimmermanP, et al.Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63:1332-1338.
15. Aleman JO, Farooki A, Girotra M. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocrine Related Cancer. 2014;21:247-259.
16. Millot F, Baruchel A, Guilhot J et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J. Clin. Oncol. 2011; 29: 2827–32.
17. Tanizawa A. Optimal management for pediatric chronic myeloid leukemia: CML in childhood. Pediatr Int. 2016;58:171–9.
18. Millot F, Guilhot J, Suttorp M et al. The experience of the international registry for chronic myeloid leukemia (CML) in children and adolescents (I-CML-Ped Study): Prognostic consideration. Blood 2014; 124: abstract 521.
19. de la Fuente J, Baruchel A, Bioindi A, et al. International BFM Study Group Chronic Myeloid Leukemia Committee. Managing children with chronic myeloid leukemia (CML). Recommendations for the management of CML in children and Young people to the age of 18 years. Br J Haematol. 2014;167:33–47.
20. Athale, Uma, et al. "Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group." Pediatric blood & cancer 66.9 (2019): e27827.
21. Kurosawa H, Tanizawa A, Muramatsu H et al. Sequential use of second generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer. 2018;65(12): e27368.
22. de Bruijn C, Millot F, Meinolf M et al. Discontinuation of imatinib in children with chronic myeloidleukaemia in sustained Deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019 May;185(4):718-724.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar